MK-8776 (SCH-900776)
mRNA synthesis
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Inhibitor Cocktails
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
SCH 900776 is a potent and selective inhibitor of cell cycle checkpoint kinase 1 (Chk1), Chk2 and Cdk3 with IC50 value of 3 nM, 1.5µM and 0.16 µM, respectively.
Chk is s serine/threonine kinase that senses signal of DNA damage and stalls DNA replication, and also plays an essential role in the maintenance of replication fork viability during exposure to DNA antimetabolites.
In vitro, SCH 900776 blocked accumulation of the Chk1 pS296 autophosphorylation in a dose-dependent manner. Treatment of proliferating WS1 cells with SCH 900776 was found to be associated with rapid, dose-dependent accumulation of Chk1 pS345, indicating that cycling populations of normal cells induce Chk1 pS345 in response to the inhibition of SCH 900776 as part of a futile cycle 1.
In BALB/c mice, administration of SCH 900776 at a dosage of 8mg/kg after gemcitabine treatment can sufficiently induce enhanced tumor pharmacodynamic and regression responses as compared to gemcitabine or SCH 900776 alone 1.
Reference:
1. Guzi TJ, Paruch K, Dwyer MP, et al. Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high
content screening. Molecular cancer therapeutics. 2011;10(4):591-602.
| Storage | Store at -20°C |
| M.Wt | 376.25 |
| Cas No. | 891494-63-6 |
| Formula | C15H18BrN7 |
| Solubility | ≥18.8mg/mL in DMSO, <1.91 mg/mL in EtOH, <1.88 mg/mL in H2O |
| Chemical Name | (R)-6-bromo-3-(1-methyl-1H-pyrazol-4-yl)-5-(piperidin-3-yl)pyrazolo[1,5-a]pyrimidin-7-amine |
| SDF | Download SDF |
| Canonical SMILES | BrC(C([[email protected]@H]1CCCNC1)=N2)=C(N)N3C2=C(C4=CN(C)N=C4)C=N3 |
| Shipping Condition | Evaluation sample solution : ship with blue ice.All other available size: ship with RT , or blue ice upon request |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. |
| Cell experiment [1]: | |
|
Cell lines |
U2OS cells |
|
Preparation method |
The solubility of this compound in DMSO is >18.8mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
|
Reacting condition |
2h |
|
Applications |
In U2OS cells, SCH 900776 induced a dose-dependent loss of DNA replication capability 24 hours after hydroxyurea exposure. SCH 900776 enhanced apoptosis for at least 48 hours following release from hydroxyurea blockade. |
| Animal experiment [1]: | |
|
Animal models |
BALB/c mice bearing A2780 xenografts |
|
Dosage form |
4-32 mg/kg |
|
Application |
SCH-900776 (8 mg/kg) led to enhanced tumor pharmacodynamic and regression responses. SCH 900776 (16 and 32 mg/kg) induced incremental improvements in tumor response. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1] Guzi T J, Paruch K, Dwyer M P, et al. Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening[J]. Molecular cancer therapeutics, 2011, 10(4): 591-602. | |
| Description | SCH 900776 is a selective inhibitor of Chk1 with an IC50 value of 3 nM. | |||||
| Targets | Chk1 | CDK2 | Chk2 | |||
| IC50 | 3 nM | 0.16 μM | 1.5 μM | |||
Quality Control & MSDS
- View current batch:
Chemical structure
Related Biological Data
